Minerva Neurosciences (NASDAQ:NERV) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a research report sent to investors on Sunday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reissued a “neutral” rating and set a $5.00 price objective on shares of Minerva Neurosciences in a report on Wednesday, November 6th.

Minerva Neurosciences Price Performance

Shares of NASDAQ:NERV opened at $2.35 on Friday. The company has a market cap of $16.43 million, a P/E ratio of -5.34 and a beta of 0.11. The stock’s fifty day moving average price is $2.26 and its 200-day moving average price is $2.65. Minerva Neurosciences has a 1 year low of $2.06 and a 1 year high of $13.49.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.